|
Immediately turn your attention to ADMD (Advanced Medical Isotope Corp. ADMD has one of the most bullish charts we’ve seen this year. After a brief period of consolidation and support coupled with news released on the company just last week, we think ADMD is primed and ready for another run north.
Currently, StockTA has ADMD showing “Bullish” EMA and MACD signals for all terms (short, intermediate and long)! StockTA also reports an overall “Bullish” analysis while BarChart.com shows the majority of its composite indicators giving a “Buy” signal!
One glance at ADMD’s chart and it’s apparent that something big is brewing. We've already seen ADMD breach hundreds of thousands of dollars in resistance to close at new 52 week highs multiple days earlier in April! Currently at .008, ADMD could be the best bargain of 2016, but we wouldn’t wait too long as prices could soar in coming sessions!
Now that you know how impressive ADMD is from a technical chart standpoint, just wait until you hear the fundamentals!
Advanced Medical Isotope Corp. (ADMD) a Kennewick, Washington-based late stage development company engaged primarily in the development of brachytherapy devices for therapeutic applications. ADMD 's focus is on transitioning to full operations upon receipt of FDA clearance for its patented brachytherapy cancer products.
Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area.Since late 2013, ADMD has focused its resources on developing a proposed line of brachytherapy products and on endeavoring to secure FDA clearance with respect to the initial proposed brachytherapy product.
ADMD’s proposed brachytherapy products incorporate patented technology developed for Battelle Memorial Institute (“Battelle”) at Pacific Northwest National Laboratory, a leading research institute for government and commercial customers. Battelle has granted ADMD an exclusive license to patents covering these developments for manufacturing, processing and applications for medical isotopes (the “Battelle License”).
A prominent team of radiochemists, scientists and engineers, collaborating with strategic partners, including national laboratories, universities and private corporations, lead ADMD’s development efforts. ADMD has been recognized as a leader in the development of new isotope technologies by local, state and federal agencies.
ADMD’s overall objective is to empower physicians, medical researchers, and ultimately, patients, by providing them with essential radionuclides that, until now, have not been practical or economical to produce, in an effort to detect, manage, and cure human disease, and improve the lives of patients. ADMD’s shorter-term objective is to obtain regulatory approval for its brachytherapy products and to then commercialize those products.
Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The Y-90 brachytherapy product is able to target cells within a narrow range, minimizing damage to normal cells. Moreover, the safety profile is noteworthy.
While traditional brachytherapy products emit radiation that may travel within and outside the body and have long half lives, the company's products use the Y-90 isotope, which travels only a short distance and has a half life of merely 2.7 days.
On March 15th, 2016, ADMD also announced the formation of a new, wholly-owned subsidiary, IsoPet Solutions Corporation, to focus on the vibrant and expanding veterinary oncology market. The IsoPet Solutions division will focus on bringing ADMD’s yttrium-90 brachytherapy products to veterinary oncologists to treat dogs and cats suffering from tumor cancers.
There are over 150 million pet dogs and cats, with over 1/3 of the households in the US owning at least one dog, and just under 1/3 owning at least one cat. IsoPet Solutions is establishing the infrastructure necessary to provide product to veterinary clinics including regulatory clearances and compliance. The division will also provide product awareness and education to veterinary oncologists.
ADMD expects the initial treatments to be coordinated through the Chair of the Company’s Veterinary Medicine Advisory Board, Dr. Alice Villalobos.
"I am quite excited at the opportunity to work with ADMD's team to integrate their products into the cancer treatments of companion animals. Cancer affects 50% of dogs over age ten and one in four dogs under age ten. For many years, we have been searching for a useable and effective agent such as ADMD’s Y-90 brachytherapy devices that can be delivered into tumors on an outpatient basis. I believe that veterinary oncologists around the globe will finally have an ideal product line for the treatment of accessible and inoperable tumors."
Dr. Alice Villobos-
Advanced Medical Isotope Announces FDA Resubmission Progress; Stands Ready to Ship First Batch of RadioGel(TM) for Veterinary Division
KENNEWICK, WA/ ACCESSWIRE / April 22, 2016 / Advanced Medical Isotope Corporation (or "AMI") (OTC: ADMD), a late stage development company engaged in the development of brachytherapy devices for therapeutic applications provides a progress update on product development, manufacturing and commercialization efforts.
AMI Founder, CEO and Chairman James C. Katzaroff stated "We have been rapidly progressing in the product development for the human and veterinary markets. AMI anticipates shipping product within the next 30 days to Washington State University for a study that is actively recruiting companion cats for the treatment of feline sarcoma. AMI is the commercialization partner under a $250,000 grant awarded to Washington State University by Washington State's Life Sciences Discovery Fund for this study. We are very pleased with the progress to date and are excited to provide our product for the initial treatments in companion animals".
You can read the full release HERE.
Be Ready to Trade at the Opening Bell Today, Tuesday April 26 at 9:30AM EST If you so choose!
|
